Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)
China · Delayed Price · Currency is CNY 9.67
+0.39 (4.20%)
Feb 3, 2026, 2:55 PM CST
SHA:603707 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 3,755 | 3,918 | 3,923 | 3,708 | 3,681 | 2,911 |
Other Revenue | 5.86 | 5.86 | 8.65 | 4.61 | 5.25 | 3.55 |
| 3,761 | 3,924 | 3,931 | 3,713 | 3,687 | 2,915 | |
Revenue Growth (YoY) | -3.00% | -0.20% | 5.89% | 0.71% | 26.48% | 18.03% |
Cost of Revenue | 2,073 | 2,112 | 3,272 | 1,778 | 1,603 | 1,236 |
Gross Profit | 1,688 | 1,812 | 659.14 | 1,935 | 2,083 | 1,679 |
Selling, General & Admin | 632.25 | 490.7 | 566.47 | 617.61 | 606.05 | 550.1 |
Research & Development | 374.69 | 329.92 | 372.29 | 263.66 | 220.95 | 187.53 |
Other Operating Expenses | 79.13 | 19.39 | 55.73 | 30.98 | 22.15 | 4.92 |
Operating Expenses | 1,087 | 848.23 | 991.45 | 913 | 851.58 | 751.05 |
Operating Income | 600.92 | 963.27 | -332.31 | 1,022 | 1,232 | 927.95 |
Interest Expense | -58.59 | -75.66 | -81.05 | -57.85 | -92.22 | -57.57 |
Interest & Investment Income | 39.23 | 21.96 | 27.98 | 60.74 | 27.53 | 11.64 |
Currency Exchange Gain (Loss) | 49.79 | 49.79 | 128.88 | 154.77 | 9.37 | 1.66 |
Other Non Operating Income (Expenses) | -18.71 | -6.17 | -1.35 | -0.65 | -2.74 | -7.04 |
EBT Excluding Unusual Items | 612.64 | 953.19 | -257.84 | 1,179 | 1,174 | 876.65 |
Gain (Loss) on Sale of Investments | 8.33 | -10.24 | -91.74 | -5.06 | 9.09 | 0.4 |
Gain (Loss) on Sale of Assets | -2.4 | -0.1 | -0.07 | -0.11 | -1.03 | -0.22 |
Asset Writedown | 55.84 | -8.58 | - | - | - | - |
Other Unusual Items | 72.77 | 57.76 | 54.89 | 12.02 | 21.98 | 37.8 |
Pretax Income | 747.18 | 992.03 | -294.76 | 1,185 | 1,204 | 914.63 |
Income Tax Expense | 97.4 | 165.93 | -105.31 | 98.85 | 139.84 | 117.98 |
Earnings From Continuing Operations | 649.78 | 826.1 | -189.45 | 1,087 | 1,064 | 796.65 |
Minority Interest in Earnings | 0.05 | 0.05 | 0 | 4.31 | -4.62 | 9.47 |
Net Income | 649.83 | 826.14 | -189.45 | 1,091 | 1,059 | 806.12 |
Net Income to Common | 649.83 | 826.14 | -189.45 | 1,091 | 1,059 | 806.12 |
Net Income Growth | - | - | - | 2.98% | 31.41% | 33.25% |
Shares Outstanding (Basic) | 1,585 | 1,620 | 1,579 | 1,628 | 1,581 | 1,588 |
Shares Outstanding (Diluted) | 1,617 | 1,652 | 1,579 | 1,628 | 1,581 | 1,588 |
Shares Change (YoY) | 1.33% | 4.66% | -3.03% | 2.98% | -0.43% | 0.94% |
EPS (Basic) | 0.41 | 0.51 | -0.12 | 0.67 | 0.67 | 0.51 |
EPS (Diluted) | 0.40 | 0.50 | -0.12 | 0.67 | 0.67 | 0.51 |
EPS Growth | - | - | - | - | 31.97% | 32.01% |
Free Cash Flow | 893.18 | 994.41 | 1,200 | 125.37 | 242.87 | -860.21 |
Free Cash Flow Per Share | 0.55 | 0.60 | 0.76 | 0.08 | 0.15 | -0.54 |
Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.115 | 0.115 | 0.089 |
Dividend Growth | - | - | -13.04% | -0.35% | 29.95% | -34.95% |
Gross Margin | 44.88% | 46.17% | 16.77% | 52.11% | 56.51% | 57.60% |
Operating Margin | 15.98% | 24.55% | -8.45% | 27.51% | 33.41% | 31.84% |
Profit Margin | 17.28% | 21.06% | -4.82% | 29.38% | 28.73% | 27.66% |
Free Cash Flow Margin | 23.75% | 25.34% | 30.53% | 3.38% | 6.59% | -29.51% |
EBITDA | 786.66 | 1,135 | -178.25 | 1,161 | 1,325 | 1,013 |
EBITDA Margin | 20.91% | 28.94% | -4.53% | 31.27% | 35.94% | 34.74% |
D&A For EBITDA | 185.74 | 172.16 | 154.06 | 139.53 | 93.22 | 84.55 |
EBIT | 600.92 | 963.27 | -332.31 | 1,022 | 1,232 | 927.95 |
EBIT Margin | 15.98% | 24.55% | -8.45% | 27.51% | 33.41% | 31.84% |
Effective Tax Rate | 13.04% | 16.73% | - | 8.34% | 11.62% | 12.90% |
Revenue as Reported | 3,761 | 3,924 | 3,931 | 3,713 | 3,687 | 2,915 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.